Home LiteratureArticle Details
PMID: 24755488 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Heparan sulfate signaling in cancer.

Trends in biochemical sciences ·Vol. 39 ·No. 6 ·2014-06-00 ·Pages 277-88

Knelson EH, Nee JC, Blobe GC

Abstract

Heparan sulfate (HS) is a biopolymer consisting of variably sulfated repeating disaccharide units. The anticoagulant heparin is a highly sulfated intracellular variant of HS. HS has demonstrated roles in embryonic development, homeostasis, and human disease via non-covalent interactions with numerous cellular proteins, including growth factors and their receptors. HS can function as a co-receptor by enhancing receptor-complex formation. In other contexts, HS disrupts signaling complexes or serves as a ligand sink. The effects of HS on growth factor signaling are tightly regulated by the actions of sulfyltransferases, sulfatases, and heparanases. HS has important emerging roles in oncogenesis, and heparin derivatives represent potential therapeutic strategies for human cancers. Here we review recent insights into HS signaling in tumor proliferation, angiogenesis, metastasis, and differentiation. A cancer-specific understanding of HS signaling could uncover potential therapeutic targets in this highly actionable signaling network.

Keywords
heparan sulfate heparanase heparin metastasis sulfatase sulfyltransferase
MeSH Terms
Animals Heparitin Sulfate/metabolism Humans Neoplasms/metabolism,pathology Signal Transduction
Chemicals
Heparitin Sulfate
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Knelson Erik H
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA; Medical Scientist Training Program, Duke University Medical Center, Durham, NC, USA.
Nee Jasmine C
Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Blobe Gerard C
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA; Department of Medicine, Duke University Medical Center, Durham, NC, USA. Electronic address: [email protected].
References (135)
135 references, click to expand
  1. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma.
    Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):E1083-91 PMID: 23471984
  2. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer.
    J Clin Invest. 1998 Nov 1;102(9):1662-73 PMID: 9802880
  3. Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma.
    J Clin Invest. 2012 Mar;122(3):911-22 PMID: 22293178
  4. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
    Am J Physiol Cell Physiol. 2010 Jul;299(1):C97-110 PMID: 20375277
  5. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7.
    J Biol Chem. 2000 Mar 10;275(10):7095-100 PMID: 10702276
  6. The overexpression of glypican-5 promotes cancer cell migration and is associated with shorter overall survival in non-small cell lung cancer.
    Oncol Lett. 2013 Dec;6(6):1565-1572 PMID: 24260047
  7. Heparin in inflammation: potential therapeutic applications beyond anticoagulation.
    Adv Pharmacol. 1999;46:151-208 PMID: 10332503
  8. Expression of GPC3 protein and its significance in lung squamous cell carcinoma.
    Med Oncol. 2012 Jun;29(2):663-9 PMID: 21556932
  9. Effect of non-anticoagulant N-desulfated heparin on basic fibroblast growth factor expression, angiogenesis, and metastasis of gastric carcinoma in vitro and in vivo.
    Gastroenterol Res Pract. 2012;2012:752940 PMID: 22888341
  10. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
    Cell. 1997 Jan 24;88(2):277-85 PMID: 9008168
  11. Heparan sulfate: a complex polymer charged with biological activity.
    Chem Rev. 2005 Jul;105(7):2745-64 PMID: 16011323
  12. Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.
    Blood. 2014 Jan 2;123(1):101-12 PMID: 24065244
  13. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling.
    EMBO J. 2006 Jul 12;25(13):3045-55 PMID: 16763549
  14. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.
    J Cell Biol. 1995 Feb;128(4):673-85 PMID: 7532175
  15. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.
    J Clin Invest. 2013 Nov;123(11):4786-98 PMID: 24216509
  16. Heparanase expression in primary and metastatic pancreatic cancer.
    Cancer Res. 2001 Jun 15;61(12):4655-9 PMID: 11406531
  17. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate.
    Expert Opin Ther Targets. 2010 Sep;14(9):935-49 PMID: 20629619
  18. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action.
    J Biol Chem. 2000 Mar 17;275(11):7964-74 PMID: 10713114
  19. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
    Cancer Res. 2002 Aug 15;62(16):4690-5 PMID: 12183427
  20. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2.
    Oncogene. 2014 Jul 3;33(27):3528-37 PMID: 23975428
  21. Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase.
    Neoplasia. 2011 May;13(5):445-52 PMID: 21532885
  22. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation.
    Cell. 1994 Dec 16;79(6):1015-24 PMID: 7528103
  23. Cell-surface co-receptors: emerging roles in signaling and human disease.
    Trends Biochem Sci. 2005 Nov;30(11):611-21 PMID: 16185874
  24. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis.
    PLoS One. 2011;6(6):e21106 PMID: 21698156
  25. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  26. From cradle to grave: the multiple roles of fibroblast growth factors in neural development.
    Neuron. 2011 Aug 25;71(4):574-88 PMID: 21867876
  27. Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer.
    Cancer Biol Ther. 2011 Sep 1;12(5):388-98 PMID: 21709440
  28. CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours.
    Pathology. 2003 Apr;35(2):125-9 PMID: 12745459
  29. Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.
    J Clin Invest. 2008 Jan;118(1):89-99 PMID: 18064304
  30. Identification of extracellular matrix ligands for the heparan sulfate proteoglycan agrin.
    Exp Cell Res. 1999 May 25;249(1):54-64 PMID: 10328953
  31. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.
    J Clin Invest. 2013 Sep;123(9):3925-40 PMID: 23925295
  32. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
    Clin Cancer Res. 2013 Feb 15;19(4):920-8 PMID: 23362325
  33. Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis.
    Neoplasia. 2007 Jun;9(6):504-10 PMID: 17603633
  34. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches.
    Exp Biol Med (Maywood). 2013 Mar;238(3):324-38 PMID: 23598979
  35. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer.
    J Mol Diagn. 2013 Jul;15(4):498-507 PMID: 23747112
  36. Role of heparan sulfate 2-o-sulfotransferase in prostate cancer cell proliferation, invasion, and growth factor signaling.
    Prostate Cancer. 2011;2011:893208 PMID: 22135748
  37. Bone morphogenetic protein 7: a broad-spectrum growth factor with multiple target therapeutic potency.
    Cytokine Growth Factor Rev. 2011 Aug;22(4):221-9 PMID: 21924665
  38. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
    Cancer Cell. 2007 Jan;11(1):53-67 PMID: 17222790
  39. Glypican-3 expression is silenced in human breast cancer.
    Oncogene. 2001 Nov 1;20(50):7408-12 PMID: 11704870
  40. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
    Neoplasia. 2011 Aug;13(8):758-70 PMID: 21847367
  41. The emerging role of TGF-beta superfamily coreceptors in cancer.
    Biochim Biophys Acta. 2009 Oct;1792(10):954-73 PMID: 19607914
  42. Heparan sulfate proteoglycans containing a glypican 5 core and 2-O-sulfo-iduronic acid function as Sonic Hedgehog co-receptors to promote proliferation.
    J Biol Chem. 2013 Sep 6;288(36):26275-26288 PMID: 23867465
  43. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.
    World J Surg Oncol. 2012 Aug 24;10:170 PMID: 22917490
  44. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo.
    J Biol Chem. 2009 Sep 18;284(38):26085-95 PMID: 19596856
  45. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor.
    Chest. 2002 Mar;121(3 Suppl):6S-7S PMID: 11893651
  46. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton.
    Prostate Cancer. 2013;2013:418340 PMID: 24396604
  47. Molecular modeling of protein-glycosaminoglycan interactions.
    Arteriosclerosis. 1989 Jan-Feb;9(1):21-32 PMID: 2463827
  48. Targeting MET in cancer: rationale and progress.
    Nat Rev Cancer. 2012 Jan 24;12(2):89-103 PMID: 22270953
  49. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
    PLoS One. 2012;7(12):e52175 PMID: 23300607
  50. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer.
    BMC Cancer. 2013 Jan 17;13:24 PMID: 23327652
  51. Amino acid determinants that drive heparan sulfate assembly in a proteoglycan.
    J Biol Chem. 1994 Jul 29;269(30):19295-9 PMID: 8034692
  52. The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.
    J Biol Chem. 2013 Mar 22;288(12):8176-8186 PMID: 23404505
  53. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.
    Mol Biol Cell. 2011 May;22(9):1463-72 PMID: 21411633
  54. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.
    Nat Cell Biol. 2013 Jul;15(7):818-28 PMID: 23792691
  55. Multi-faceted substrate specificity of heparanase.
    Matrix Biol. 2013 Jun 24;32(5):223-7 PMID: 23499529
  56. The role of syndecan-1 in malignancies.
    Ann Med. 1996 Feb;28(1):63-7 PMID: 8932508
  57. Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
    Cancer Res. 2005 Nov 1;65(21):9899-905 PMID: 16267014
  58. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.
    Cell Signal. 2009 Nov;21(11):1548-58 PMID: 19427900
  59. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets.
    Future Oncol. 2008 Dec;4(6):803-14 PMID: 19086847
  60. Heparitin sulfate.
    Biochim Biophys Acta. 1958 Aug;29(2):443-4 PMID: 13572372
  61. The type III TGF-beta receptor suppresses breast cancer progression.
    J Clin Invest. 2007 Jan;117(1):206-17 PMID: 17160136
  62. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.
    J Clin Invest. 2014 Jul;124(7):3016-31 PMID: 24937430
  63. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
    Clin Cancer Res. 2011 Mar 15;17(6):1382-93 PMID: 21257720
  64. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement.
    J Biol Chem. 1981 Nov 10;256(21):11065-72 PMID: 7287751
  65. Heparan sulfate proteoglycans: intricate molecules with intriguing functions.
    J Clin Invest. 2001 Jul;108(2):165-7 PMID: 11457866
  66. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma.
    Lab Invest. 2006 Nov;86(11):1149-60 PMID: 16983329
  67. The complex effects of heparins on cancer progression and metastasis in experimental studies.
    Pharmacol Rev. 2001 Mar;53(1):93-105 PMID: 11171940
  68. Microvascular heparin-like species with anticoagulant activity.
    Am J Physiol. 1983 Nov;245(5 Pt 1):H725-33 PMID: 6356938
  69. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
    Invasion Metastasis. 1994-1995;14(1-6):290-302 PMID: 7657522
  70. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation.
    Mol Cancer Res. 2008 Jan;6(1):1-9 PMID: 18234958
  71. The multiple functions of collagen XVIII in development and disease.
    Matrix Biol. 2011 Mar;30(2):83-92 PMID: 21163348
  72. Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.
    Int J Cancer. 2009 Nov 1;125(9):2058-65 PMID: 19598263
  73. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells.
    J Biol Chem. 2002 Aug 16;277(33):29730-6 PMID: 12055189
  74. Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity.
    Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7003-11 PMID: 16203794
  75. Heparan sulfate proteoglycan expression in human lung-cancer cells.
    Int J Cancer. 1997 Jun 20;74(3):335-45 PMID: 9221815
  76. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis.
    J Gastrointest Cancer. 2008;39(1-4):149-58 PMID: 19373441
  77. Role for amplification and expression of glypican-5 in rhabdomyosarcoma.
    Cancer Res. 2007 Jan 1;67(1):57-65 PMID: 17210683
  78. Roles for the type III TGF-beta receptor in human cancer.
    Cell Signal. 2010 Aug;22(8):1163-74 PMID: 20153821
  79. Heparin and heparan sulfate: structure and function.
    Nat Prod Rep. 2002 Jun;19(3):312-31 PMID: 12137280
  80. CD44 is required for two consecutive steps in HGF/c-Met signaling.
    Genes Dev. 2002 Dec 1;16(23):3074-86 PMID: 12464636
  81. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena.
    J Clin Invest. 2001 Aug;108(3):349-55 PMID: 11489925
  82. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.
    Neoplasia. 2013 Feb;15(2):112-24 PMID: 23441126
  83. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis.
    J Cell Mol Med. 2011 May;15(5):1013-31 PMID: 21155971
  84. Order out of chaos: assembly of ligand binding sites in heparan sulfate.
    Annu Rev Biochem. 2002;71:435-71 PMID: 12045103
  85. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins.
    Int J Cell Biol. 2012;2012:676731 PMID: 22505933
  86. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.
    J Cell Biol. 2005 Nov 21;171(4):729-38 PMID: 16286510
  87. Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition.
    Cancer Res. 2013 Dec 1;73(23):7111-21 PMID: 24121493
  88. Heparan sulfate proteoglycans retain Noggin at the cell surface: a potential mechanism for shaping bone morphogenetic protein gradients.
    J Biol Chem. 2002 Jan 18;277(3):2089-96 PMID: 11706034
  89. Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism.
    J Biol Chem. 2011 Jul 22;286(29):25947-62 PMID: 21596751
  90. In vivo footprinting analysis of the Glypican 3 (GPC3) promoter region in neuroblastoma cells.
    Biochim Biophys Acta. 2007 Mar;1769(3):182-93 PMID: 17350117
  91. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
    Carcinogenesis. 2009 Mar;30(3):397-407 PMID: 19126645
  92. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
    Clin Cancer Res. 2004 Aug 1;10(15):5178-86 PMID: 15297422
  93. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
    Cancer Res. 2001 Jul 15;61(14):5562-9 PMID: 11454708
  94. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis.
    J Clin Invest. 2001 Aug;108(3):341-7 PMID: 11489924
  95. Stromal endothelial cells directly influence cancer progression.
    Sci Transl Med. 2011 Jan 19;3(66):66ra5 PMID: 21248315
  96. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix.
    J Pathol. 1994 Apr;172(4):349-55 PMID: 8207616
  97. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis.
    Oncogene. 2006 Mar 2;25(9):1408-12 PMID: 16247452
  98. Epigenetic inactivation of heparan sulfate (glucosamine) 3-O-sulfotransferase 2 in lung cancer and its role in tumorigenesis.
    PLoS One. 2013 Nov 12;8(11):e79634 PMID: 24265783
  99. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
    Hepatology. 2008 Apr;47(4):1211-22 PMID: 18318435
  100. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
    Mol Cancer Ther. 2013 Jul;12(7):1190-201 PMID: 23696215
  101. Heparin-protein interactions.
    Angew Chem Int Ed Engl. 2002 Feb 1;41(3):391-412 PMID: 12491369
  102. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.
    Ann Oncol. 2010 Jun;21(6):1302-1307 PMID: 19917571
  103. miR-331-3p regulates expression of neuropilin-2 in glioblastoma.
    J Neurooncol. 2014 Jan;116(1):67-75 PMID: 24142150
  104. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.
    J Hepatol. 2009 May;50(5):958-68 PMID: 19303160
  105. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
    J Biol Chem. 2007 May 4;282(18):13326-33 PMID: 17347152
  106. Heparan sulfate is required for bone morphogenetic protein-7 signaling.
    Biochem Biophys Res Commun. 2003 Sep 5;308(4):858-65 PMID: 12927798
  107. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study.
    Lancet Oncol. 2010 Apr;11(4):321-30 PMID: 20304703
  108. Fibroblast growth factor signalling: from development to cancer.
    Nat Rev Cancer. 2010 Feb;10(2):116-29 PMID: 20094046
  109. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis.
    Mol Cancer Res. 2012 May;10(5):597-604 PMID: 22522458
  110. Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma.
    Hum Pathol. 2007 Oct;38(10):1508-15 PMID: 17640714
  111. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions.
    J Biol Chem. 1998 Aug 28;273(35):22825-32 PMID: 9712917
  112. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis.
    Thorax. 2013 May;68(5):442-50 PMID: 23321607
  113. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach.
    Mol Cell Proteomics. 2006 Jan;5(1):157-71 PMID: 16215274
  114. Expression and prognostic role of syndecan-2 in prostate cancer.
    Prostate Cancer Prostatic Dis. 2010 Mar;13(1):78-82 PMID: 19786981
  115. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.
    Urol Oncol. 2010 Sep-Oct;28(5):534-40 PMID: 19450993
  116. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis.
    J Biol Chem. 2000 Aug 11;275(32):24653-60 PMID: 10816596
  117. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88.
    Glycobiology. 2010 Feb;20(2):175-86 PMID: 19822709
  118. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins.
    FASEB J. 2007 Nov;21(13):3562-72 PMID: 17557930
  119. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis.
    Cell. 1994 Dec 16;79(6):1005-13 PMID: 7528102
  120. Immunohistochemical study of glypican 3 in thyroid cancer.
    Oncology. 2007;73(5-6):389-94 PMID: 18511877
  121. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours.
    Eur J Cancer. 2004 Jun;40(9):1373-82 PMID: 15177497
  122. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo.
    Int J Cancer. 2010 Mar 15;126(6):1291-301 PMID: 19816934
  123. Targeting the PDGF signaling pathway in tumor treatment.
    Cell Commun Signal. 2013 Dec 20;11:97 PMID: 24359404
  124. The effect of anticoagulants on cancer risk and survival: systematic review.
    Cancer Treat Rev. 2007 Jun;33(4):358-68 PMID: 17408861
  125. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
    Am J Surg Pathol. 2008 Apr;32(4):600-7 PMID: 18277882
  126. Nonheparin anticoagulants for heparin-induced thrombocytopenia.
    N Engl J Med. 2013 Feb 21;368(8):737-44 PMID: 23425166
  127. Redistribution of aquaporin-4 in human glioblastoma correlates with loss of agrin immunoreactivity from brain capillary basal laminae.
    Acta Neuropathol. 2004 Apr;107(4):311-8 PMID: 14735305
  128. Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1.
    J Biol Chem. 2003 Apr 11;278(15):13069-76 PMID: 12556525
  129. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway.
    Carcinogenesis. 2008 Jul;29(7):1319-26 PMID: 18413366
  130. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma.
    Cancer. 2002 Jan 1;94(1):258-63 PMID: 11815985
  131. The utility of hedgehog signaling pathway inhibition for cancer.
    Oncologist. 2012;17(8):1090-9 PMID: 22851551
  132. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo.
    J Clin Invest. 1998 Oct 15;102(8):1599-608 PMID: 9788974
  133. Neuropilins in tumor biology.
    Clin Cancer Res. 2009 Mar 15;15(6):1860-4 PMID: 19240167
  134. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer.
    Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):627-38 PMID: 19822079
  135. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis.
    Mol Cells. 2009 May 31;27(5):503-13 PMID: 19466598
Article Info
Journal
Trends in biochemical sciences
Abbr.
Trends Biochem Sci
ISSN
0968-0004
Published
2014-06-00
Epub
2014-00-19
Pages
277-88
Language
English
Region
England
NLM ID
7610674
PMCID
PMC4065786
Subset
IM
Grants
NCI NIH HHS · F30 CA168043-01 · United States
NCI NIH HHS · R01-CA136786 · United States
NCI NIH HHS · F30 CA168043 · United States
NCI NIH HHS · R01 CA135006 · United States
NCI NIH HHS · R01 CA136786 · United States
NIGMS NIH HHS · T32 GM007171 · United States
NCI NIH HHS · R01-CA135006 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]